Reports Q1 revenue $195.9M, consensus $200.51M. “We had a challenging first quarter of 2025 with strength in our prenatal and oncology MyRisk tests offset by softness in GeneSight and unaffected hereditary cancer tests. While we are actively working on initiatives to re-accelerate testing volumes, this will take time; therefore we are lowering our 2025 financial guidance. We are taking immediate steps to reduce overall expenditures while prioritizing investment in new product development and programs intended to drive revenue growth,” said Sam Raha, President and CEO, of Myriad Genetics (MYGN).
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MYGN:
- Myriad Genetics announces survey results on depression, anxiety
- MYGN Upcoming Earnings Report: What to Expect?
- Myriad says GeneSight Psychotropic Test led to fewer hospitalizations in study
- Myriad Genetics price target lowered to $9 from $11 at BofA
- Myriad Genetics downgraded to Neutral from Buy at Guggenheim